Allogene Therapeutics Inc Cash Flow Conversion Efficiency
Allogene Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Allogene Therapeutics Inc (ALLO) has a cash flow conversion efficiency ratio of -0.094x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.69 Million) by net assets ($315.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Allogene Therapeutics Inc (2017–2024)
Cash flow conversion efficiency of Allogene Therapeutics Inc from 2017 to 2024. This chart illustrates how Allogene Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Allogene Therapeutics Inc for real-time trading data and today's change.
Allogene Therapeutics Inc Cash Flow Conversion Ratio Explained
Allogene Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Allogene Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Allogene Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Allogene Therapeutics Inc (ALLO) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WAWEL SA
WAR:WWL
|
0.019x |
|
Zespol Elektrowni Patnow Adamow Konin SA
WAR:ZEP
|
0.081x |
|
Lionheart Holdings
NASDAQ:CUB
|
0.000x |
|
Caswell Inc
TW:6416
|
-0.038x |
|
Clinuvel Pharmaceuticals Ltd
AU:CUV
|
0.050x |
|
INTERGRATED DIA.H DL 025
F:8I8
|
0.096x |
|
NEOBO FASTIGHETER
ST:NEOBO
|
0.006x |
|
P.C.B Tec
TA:PCBT
|
0.056x |
Annual Cash Flow Conversion Efficiency for Allogene Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Allogene Therapeutics Inc from 2017 to 2024. Review ALLO cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $422.18 Million | $-200.30 Million | -0.474x | -2.23% |
| 2023-12-31 | $512.23 Million | $-237.73 Million | -0.464x | -40.35% |
| 2022-12-31 | $666.88 Million | $-220.52 Million | -0.331x | -65.54% |
| 2021-12-31 | $925.20 Million | $-184.81 Million | -0.200x | -87.38% |
| 2020-12-31 | $1.08 Billion | $-115.09 Million | -0.107x | +51.18% |
| 2019-12-31 | $629.02 Million | $-137.35 Million | -0.218x | -243.85% |
| 2018-12-31 | $703.16 Million | $-44.65 Million | -0.064x | -100.00% |
| 2017-12-31 | $-2.00K | $-44.65 Million | 22326.500x | -- |
About Allogene Therapeutics Inc
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell a… Read more